Alopecia Areata Market Expected to Expand by 2036 with Novel Therapies in Development

The alopecia areata market is expected to grow significantly as awareness of the condition increases, potentially expanding further in the coming years, supported by rising prevalence. The total alopecia areata treatment market size is expected to grow positively by 2036 in the leading markets.

In 2025, the total diagnosed prevalent cases of alopecia areata in the 7MM were found to be 1.7 million. In 2024, the United States recorded the highest number of diagnosed prevalent cases of alopecia areata among the 7MM, with approximately 620K diagnosed cases in the US that year, with projections indicating a continued increase throughout the forecast period. The United States accounts for the largest market size of alopecia areata, in comparison to EU4 (Germany, Italy, France, and Spain), the UK, and Japan.

Alopecia areata is a chronic autoimmune disease characterized by a breakdown of immune privilege, resulting in an inflammatory response to hair follicles that can cause hair loss. Approximately 0.2% of individuals in the US have AA, with many having moderate to severe disease that presents with greater amounts of hair loss. The estimated prevalence of moderate to severe disease—sometimes defined as greater than 50% scalp involvement, including AT and AU—ranges from approximately 35% to 43% among patients with AA.

The JAK-STAT pathway is pivotal to the inflammatory response following the collapse of immune privilege in AA. Three JAK inhibitors are currently FDA-approved for severe AA: baricitinib, ritlecitinib, and deuruxolitinib. A limited number of therapies are currently approved for the treatment of alopecia areata, underscoring the field's strong emphasis on immune-modulating mechanisms. Approved options include OLUMIANT, a small-molecule JAK inhibitor; LITFULO, a selective JAK3 and TEC kinase inhibitor; and LEQSELVI, a JAK1/JAK2 inhibitor.

The first systemic, targeted medicines for alopecia areata, notably baricitinib (OLUMIANT) and ritlecitinib (LITFULO), changed the treatment landscape by providing reproducible, clinically meaningful hair regrowth in controlled trials. Regulatory clearances create prescribing options, attract payer attention, and validate JAK inhibition as a therapeutic approach.

Despite these advancements, a substantial unmet need persists, as currently available treatments do not consistently deliver durable or complete disease control across patient populations. This therapeutic gap continues to drive innovation, positioning next-generation, differentiated therapies as key opportunities to improve clinical outcomes and expand the treatment landscape for alopecia areata.

The dynamics of the alopecia areata market are expected to change in the coming years due to the launch of emerging therapies such as RINVOQ (AbbVie), Bempikibart (Q32 Bio), Coacillium (Legacy Healthcare), ALM 223 (Almirall), Amlitelimab (Sanofi), HCW9302 (HCW Biologics), ALY-101 (ALYS Pharmaceuticals), DR-01 (Dren Bio), Rezpegaldesleukin (Nektar Therapeutics), and others. Emerging therapies, including OX40L and IL-2 inhibitors, are strengthening the alopecia areata landscape by targeting the disease's root causes and offering precision in treatment.

The current market offers a broad range of treatment options, including corticosteroids, immunosuppressants, immunomodulators, and topical sensitizers or irritants. Corticosteroids continue to play a central role due to their anti-inflammatory effects, helping reduce immune-mediated attacks on hair follicles.

Beyond its visible manifestations, AA imposes a considerable psychosocial burden and substantial economic impact due to increased health care utilization. Individuals with AA experience a higher prevalence of several autoimmune, cardiovascular, and psychiatric comorbidities and also experience negative impacts on health-related quality of life, psychosocial well-being, and functioning at work and school related to AA.